Meeting
2017 ASCO Annual Meeting
Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma.
Authors
Manisha H. Shah
Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
Manisha H. Shah , Lai Wei , Lori J. Wirth , Gregory A. Daniels , Jonas A. De Souza , Cynthia Dawn Timmers , Jennifer L. Sexton , Mamdouh Beshara , Debra Nichols , Norka Snyder , Catherine E Devine , Bhavana Konda , Naifa Lamki Busaidy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT01723202
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6022)
DOI
10.1200/JCO.2017.35.15_suppl.6022
Abstract #
6022
Poster Bd #
10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H.
First Author: April K.S. Salama
Poster
2023 ASCO Annual Meeting
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
First Author: Gregory J. Riely
Poster
2021 ASCO Annual Meeting
A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated BRAFV600/NRASQ61R/K/L wild-type melanoma (TraMel-WT): Interim efficacy and safety results.
First Author: Gil Awada
Poster
2012 ASCO Annual Meeting
BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).
First Author: Ryan Bruce Corcoran